These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

5608 related items for PubMed ID: 3149257

  • 1. Comparison of thrombolytic, fibrinolytic, and fibrinogenolytic properties of tissue plasminogen activator, streptokinase, single-chain urokinase, high molecular weight and low molecular weight urokinase in human plasma in vitro.
    Samama M, Nguyen G, Desnoyers P, Lourenco DM, Fretault J, Horellou MH, Conard J, Szwarcer E, Verdy E, Vahanian A.
    Fundam Clin Pharmacol; 1988; 2(6):509-23. PubMed ID: 3149257
    [Abstract] [Full Text] [Related]

  • 2. [New thrombolytic agents].
    Nguyen G, Samama M.
    Ann Biol Clin (Paris); 1987; 45(2):212-8. PubMed ID: 3113300
    [Abstract] [Full Text] [Related]

  • 3. [New thrombolytic agents in myocardial infarction].
    Charbonnier B, Lang M, Brochier M.
    Arch Mal Coeur Vaiss; 1987 Nov; 80(12):1785-91. PubMed ID: 3128222
    [Abstract] [Full Text] [Related]

  • 4. Synergy of in vitro thrombolytic action of combinations of recombinant staphylokinase and single-chain urokinase-type plasminogen activator.
    Aisina RB, Moukhametova LI, Varfolomeyev SD.
    Biochemistry (Mosc); 2003 Nov; 68(11):1252-60. PubMed ID: 14640969
    [Abstract] [Full Text] [Related]

  • 5. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D, De Cock F, Demarsin E, Lijnen HR, Stump DC.
    Thromb Haemost; 1986 Aug 20; 56(1):35-9. PubMed ID: 3095946
    [Abstract] [Full Text] [Related]

  • 6. Effect of standard heparin and a low molecular weight heparin on thrombolytic and fibrinolytic activity of single-chain urokinase plasminogen activator in vitro.
    Lourenço DM, Dosne AM, Kher A, Samama M.
    Thromb Haemost; 1989 Nov 24; 62(3):923-6. PubMed ID: 2556812
    [Abstract] [Full Text] [Related]

  • 7. Thrombolytic and pharmacokinetic properties of chimeric tissue-type and urokinase-type plasminogen activators.
    Collen D, Lu HR, Lijnen HR, Nelles L, Stassen JM.
    Circulation; 1991 Sep 24; 84(3):1216-34. PubMed ID: 1909220
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparative thrombolytic properties of single-chain forms of urokinase-type plasminogen activator.
    Stump DC, Stassen JM, Demarsin E, Collen D.
    Blood; 1987 Feb 24; 69(2):592-6. PubMed ID: 3099862
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Potentiation by Lys-plasminogen of clot lysis by single or two chain urokinase-type plasminogen activator or tissue-type plasminogen activator.
    Watahiki Y, Scully MF, Ellis V, Kakkar VV.
    Thromb Haemost; 1989 Jun 30; 61(3):502-6. PubMed ID: 2508259
    [Abstract] [Full Text] [Related]

  • 12. Purification and characterization of a novel low molecular weight form of single-chain urokinase-type plasminogen activator.
    Stump DC, Lijnen HR, Collen D.
    J Biol Chem; 1986 Dec 25; 261(36):17120-6. PubMed ID: 3097021
    [Abstract] [Full Text] [Related]

  • 13. Pharmacology of thrombolytic drugs.
    Verstraete M, Collen D.
    J Am Coll Cardiol; 1986 Dec 25; 8(6 Suppl B):33B-40B. PubMed ID: 3097100
    [Abstract] [Full Text] [Related]

  • 14. In vitro studies on the fibrinolytic, thrombolytic and fibrinogenolytic properties of a tissue plasminogen activator from guinea pig keratocytes.
    Electricwala A, Ling RJ, Sutton PM, Griffiths B, Riley PA, Atkinson T.
    Thromb Haemost; 1985 Apr 22; 53(2):200-3. PubMed ID: 4040659
    [Abstract] [Full Text] [Related]

  • 15. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--I. Fibrinolytic and fibrinogenolytic properties in human plasma in vitro of urokinases obtained from human urine or by recombinant DNA technology.
    Zamarron C, Lijnen HR, Van Hoef B, Collen D.
    Thromb Haemost; 1984 Aug 31; 52(1):19-23. PubMed ID: 6495259
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of the in vitro fibrinolytic activities of low and high molecular weight single-chain urokinase-type plasminogen activator.
    de Munk GA, Groeneveld E, Rijken DC.
    Thromb Haemost; 1993 Sep 01; 70(3):481-5. PubMed ID: 8259553
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species.
    Lijnen HR, De Wreede K, Demarsin E, Collen D.
    Thromb Haemost; 1984 Aug 31; 52(1):31-3. PubMed ID: 6495261
    [Abstract] [Full Text] [Related]

  • 20. New developments in thrombolytic therapy.
    Collen D, Gold HK.
    Adv Exp Med Biol; 1990 Aug 31; 281():333-54. PubMed ID: 2129372
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 281.